Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3

Journal of Molecular Biology

Volumn 356, Issue 4, 2006, Pages 967-981

  Heaslet, Holly ^a   Kutilek, Victoria ^a,b   Morris, Garrett M ^a   Lin, Ying Chuan ^a   Elder, John H ^a   Torbett, Bruce E ^a   Stout, C David ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Crystal structure; Drug resistance; HIV 1 protease; Mutation; Viral evolution

Indexed keywords

PROTEASE NL3; PROTEASE NL4; PROTEINASE; PROTEINASE INHIBITOR; TL 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CONFORMATION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG MECHANISM; ENZYME MECHANISM; ENZYME STRUCTURE; EX VIVO STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FOLDING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 31344456746     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2005.11.094     Document Type: Article

References (43)

1. B. Hirschel, and P. Francioli Progress and problems in the fight against AIDS N. Engl. J. Med. 338 1998 906 908
2. R.S. Hogg, M.V. O'Shaughnessy, N. Gataric, B. Yip, K. Craib, M.T. Schechter, and J.S. Montaner Decline in deaths from AIDS due to new antiretrovirals Lancet 349 1997 1294
3. R.S. Hogg, K.V. Heath, B. Yip, K.J. Craib, M.V. O'Shaughnessy, M.T. Schechter, and J.S. Montaner Improved survival among HIV-infected individuals following initiation of antiretroviral therapy J. Am. Med. Assoc. 279 1998 450 454
4. T. Ridky, and J. Leis Development of drug resistance to HIV-1 protease inhibitors J. Biol. Chem. 270 1995 29621 29623
5. J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, and J. Quintero In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors Nature 374 1995 569 571
6. T. Lee, G.S. Laco, B.E. Torbett, H.S. Fox, D.L. Lerner, J.H. Elder, and C.-H. Wong Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo Proc. Natl Acad. Sci. USA 95 1998 939 944
7. T. Lee, V.-D. Le, D. Lim, Y.C. Lin, G.M. Morris, and A.L. Wong Development of a new type of protease inhibitors, efficacious against FIV and HIV variants J. Am. Chem. Soc. 121 1999 1145 1155
8. B. Buhler, Y.C. Lin, G. Morris, A.J. Olson, C.-H. Wong, and D.D. Richman Viral evolution in response to the broad-based retroviral protease inhibitor TL-3 J. Virol. 75 2001 9502 9508
9. R.J. Read Improved Fourier coefficients for maps using phases from partial structures with errors Acta Crystallog. sect. A 42 1986 140 149
10. B.C. Logsdon, J.F. Vickrey, P. Martin, G. Proteasa, J.I. Koepke, and S.R. Terlecky Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal expanded active-site cavity J. Virol. 78 2004 3123 3132
11. T.A. Binkowski, S. Naghibzadeh, and J. Liang CASTp: computed atlas of surface topography of proteins Nucl. Acids Res. 31 2003 3352 3355
12. E.T. Baldwin, T.N. Bhat, B. Liu, N. Pattabiraman, and J.W. Erickson Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase Nature Struct. Biol. 2 1995 244 249
13. M. Prabu-Jeyalbalan, E. Nalivaika, N.M. King, and C.A. Schiffer Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease J. Virol. 78 2004 12446 12454
14. R.W. Shafer, D. Stevenson, and B. Chan Human immunodeficiency virus reverse transcriptase and protease sequence database Nucl. Acids Res. 27 1999 348 352
15. Z. Chen, Y. Li, E. Chen, D.L. Hall, P.L. Darke, and C. Culberson Crystal structure at 1.9 Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases J. Biol. Chem. 269 1994 26344 26348
16. S.W. Kaldor, V.J. Kalish, J.F. Davies, B.V. Shetty, J.E. Fritz, and K. Applet Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease J. Med. Chem. 40 1997 3979 3985
17. D.J. Kemf, K.C. Marsh, J.F. Denissen, E. McDonald, S. Vasavanonda, and C.A. Flentge ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans Proc. Natl Acad. Sci. USA 92 1995 2484 2488
18. E.E. Kim, C.T. Baker, M.D. Dwyer, M.A. Murcko, B.G. Roa, R.D. Tung, and M.A. Navia Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhbitor of the enzyme J. Am. Chem. Soc. 117 1995 1181 1182
19. M. Prabu-Jeyalbalan, E. Nalivaika, N.M. King, and C.A. Schiffer Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy J. Virol. 77 2003 1306 1315
20. J. Kervinen, N. Thanki, A. Zdanov, J. Tino, J. Barrish, and P.F. Lin Structural analysis of the native and drug-resistant HIV-1 proteinases complexed with an aminodiol inhibitor Protein Pept. Letters 3 1996 399 406
21. J.C. Clemente, R.E. Moose, R. Hemrajani, L.R.S. Whitford, L. Govindasamy, and R. Reutzel Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease Biochemistry 43 2004 12141 12151
22. B. Mahalingham, Y.-F. Wang, P.I. Boross, J. Tozser, J.M. Louis, R.W. Harrison, and I.T. Weber Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site Eur. J. Biochem. 271 2004 1516 1524
23. Y. Tie, P.I. Boross, Y.-F. Wang, L. Gaddis, A.K. Hussain, and S. Leshchenko High resolution crystal structures of HIV-1 protease with a potent non-peptide inhbitor (UIC-94017) active against multi-drug-resistant clinical strains J. Mol. Biol. 338 2004 341 352
24. J. Tozser, F.H. Yin, Y.-S.E. Cheng, P. Bagossi, I.T. Weber, R.W. Harrison, and S. Oroszlan Activity of tethered human immunodeficiency virus 1 protease containing mutations in the flap region on one subunit Eur. J. Biochem. 244 1997 235 241
25. W.R.P. Scott, and C.A. Schiffer Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance Structure 8 2000 1259 1265
26. K.K. Reiling, N.F. Endres, D.S. Dauber, C.S. Craik, and R.M. Stroud Anisotropic dynamics of the Je-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 Å structure Biochemistry 41 2002 4582 4594
27. E. Chen Host strain selection for bacterial expression of toxic proteins L.C. Kuo J.A. Shafer Methods in Enzymology vol. 241 1994 Elsevier San Diego, CA 29 46
28. M. Prabu-Jeyalbalan, E. Nalivaika, and C.A. Schiffer Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes Structure 10 2002 369 381
29. C. Chothia Hydrophobic bonding and accessible surface area in proteins Nature 248 1974 338 339
30. C. Chothia The nature of accessible and buried surfaces in proteins J. Mol. Biol. 105 1976 1 12
31. M. Rajabzadeh, J. Kao, and C. Frieden Consequences of single-site mutations in the intestinal fatty acid binding protein Biochemistry 42 2003 12192 12199
32. R.B. Rose, J.R. Rose, R. Salto, C.S. Craik, and R.M. Stroud Structure of the protease from simian immunodeficiency virus: complex with an irreversible nonpeptide inhibitor Biochemistry 32 1993 12498 12507
33. W.F. Studier, A.H. Rosenberg, J.J. Dunn, and J.W. Dubendorff Use of T7 RNA polymerase to direct expression of cloned genes D.V. Goeddel Methods in Enzymology vol. 185 1990 Academic Press San Diego, CA 60 89
34. J.F. Vickrey, B.C. Logsdon, G. Proteasa, S. Palmer, M.A. Winters, T.C. Merigan, and L.C. Kovari HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization Protein Expr. Purif. 28 2002 165 172
35. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
36. J.W. Pflugrath The finer things in X-ray diffraction data collection Acta Crystallog. sect. D 55 1999 1718 1725
37. A.G.W. Leslie Recent changes to the MOSFLM package for processing film and image plate data Joint CCP4+ESF-EAMCB Newsletter Protein Crystallog. 26 1992
38. A. Vagin, and A. Teplyakov An approach to multi-copy search in molecular replacement Acta Crystallog. sect. D 56 2000 1622 1624
39. A.T. Brünger The free R value: a novel statistical quantity for assessing the accuracy of crystal structures Nature 355 1992 472 474
40. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallog. sect. D 53 1997 240 255
41. A.T. Brünger, P.D. Adams, G.M. Clore, P. Gros, R.W. Grosse-Kunstleve, and J.-S. Jiang Crystallography & NMR system (CNS): a new software system for macromolecular structure determination Acta Crystallog. sect. D 54 1998 905 921
42. T.A. Jones, J.Y. Zou, S.W. Cowan, and M. Kjelgaard Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallog. sect. A 47 1991 110 119
43. M. Li, G.M. Morris, T. Lee, G.S. Laco, C.-H. Wong, and A.J. Olson Structural studies of FIV and HIV-1 protease complexed with an efficient inhibitor of FIV protease Proteins: Struct., Funct. Genet. 38 2000 29 40